Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A MULTI-ARM PHASE 1 DOSE ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITORS PF-04691502 AND PF-05212384 IN COMBINATION WITH EXPERIMENTAL OR APPROVED ANTICANCER AGENTS IN PATIENTS WITH ADVANCED CANCER.

 


A MULTI-ARM PHASE 1 DOSE ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITORS PF-04691502 AND PF-05212384 IN COMBINATION WITH EXPERIMENTAL OR APPROVED ANTICANCER AGENTS IN PATIENTS WITH ADVANCED CANCER.


Trial Focus

All Cancers

Objective

         This clinical trial is being done to study three investigational drugs called PD-0325901, PF-05212384, and PF-04691502. These study drugs are being looked at to see if they could be a treatment for advanced cancer. You will be given only one of the three

IRB Protocol #

11-1085

Trial Status

OPEN

Principle Investigator

STEPHEN LEONG

Sponsor

Pfizer

Contact

ALISON SUTTON at (720)848-0601 or ALISON.SUTTON@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will take place to determine eligibility. The number of treatment cycles you receive will depend on how you are doing. You may continue to receive the study drug for up to a year or until your disease progresses or if you develop side-effects. However, you may continue with the study drug if your study doctor determines that your cancer is not growing. Follow up visits will occur once the study concludes. // Those who are 18 years or older with advanced cancer may be eligible for to participate in this study.Those who are 18 years or older with advanced cancer may be eligible for to participate in this study.